Share chart Ligand Pharmaceuticals Incorporated
Extended chart
Simple chart
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.Main settings
IPO date
1992-11-18
ISIN
US53220K5048
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Дивиденд ао
0.456
Сайт
Grade
Underestimation
Title | Value | Grade |
P/S | 11.57 | 1 |
P/BV | 2.33 | 6 |
P/E | 24.35 | 6 |
Efficiency
Title | Value | Grade |
ROA | -0.4664 | 0 |
ROE | -0.5266 | 0 |
ROIC | 0 | 0 |
Dividends
Title | Value | Grade |
Dividend yield | 0 | 0 |
DSI | 0.5 | 5 |
Average dividend growth | -1011.4 | 0 |
Debt
Title | Value | Grade |
Debt/EBITDA | 0.1655 | 10 |
Debt/Ratio | 0.0075 | 10 |
Debt/Equity | 0.1341 | 10 |
Growth impulse
Title | Value | Grade |
Yield Revenue, % | -10.34 | 0 |
Yield Ebitda, % | 34.19 | 5 |
Yield EPS, % | 24.27 | 4 |
Prices
Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
Yesterday | 112.5 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
Week | 113.42 $ | 0 $ | 0 $ | -0.8111 % | 0 % | 0 % |
Month | 101.6 $ | 112.5 $ | 112.5 $ | +10.73 % | 0 % | 0 % |
Three month | 104.27 $ | 100.19 $ | 115.39 $ | +7.89 % | 0 % | 0 % |
Half a year | 117.84 $ | 96.67 $ | 122.23 $ | -4.53 % | 0 % | 0 % |
Year | 106.54 $ | 93.32 $ | 129.9 $ | +5.59 % | 0 % | 0 % |
3 years | 60.2 $ | 48.1 $ | 129.9 $ | +86.88 % | 0 % | 0 % |
5 years | 117.93 $ | 48.1 $ | 215.83 $ | -4.6 % | 0 % | 0 % |
10 years | 48.1 $ | 48.1 $ | 274.49 $ | +233.91 % | 0 % | 0 % |
Year to date | 117.28 $ | 96.67 $ | 122.23 $ | -4.08 % | 0 % | 0 % |
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
Syntax Stratified SmallCap ETF | 0.3841 | -1.44 | 0.40 |
IndexIQ ETF Trust IQ U.S. Small Cap ETF | 0.25 | 54.74 | 0.35 |
Future Tech ETF | 0.1841 | 479.5 | 0.35 |
Principal Healthcare Innovators ETF | 0.1841 | -3.92 | 0.35 |
iShares Morningstar Small-Cap Growth ETF | 0.04601 | 570.49 | 0.06 |
iShares Morningstar Small-Cap ETF | 0.0404 | 301.34 | 0.25 |
iShares Morningstar Small-Cap Value ETF | 0.03432 | 175.74 | 0.06 |
0.16 | 225.21 | 0.26 |
---|
Similar companies
P/E & P/BV
Company management
Head | Job title | Payment | Year of birth |
Mr. Matthew E. Korenberg | President & COO | 831.77k | 1975 (50 years) |
Mr. Octavio Espinoza | Chief Financial Officer | 613.59k | 1971 (54 years) |
Mr. Andrew T. Reardon J.D. | Chief Legal Officer & Secretary | 614.87k | 1975 (50 years) |
Mr. Todd Pettingill | Director of Corporate Development | N/A | |
Dr. Keith Marschke | Senior Vice President of Biology & Scientific Affairs | N/A | |
Dr. Vincent D. Antle | Senior Vice President of Technical Operations & QA - Capitsol | N/A | 1969 (56 years) |
Mr. Paul J. Hadden | Senior Vice President of Investments & Business Development | N/A | |
Mr. Patrick Lucy | Senior VP & CBO Protein Expression Business | N/A | |
Mr. Todd C. Davis Ph.D. | CEO & Director | 1961 (64 years) | |
Michael Jeong | Head of Investor Relations |
About company
Address: United States, San Diego. CA, 3911 Sorrento Valley Boulevard - Open in google maps, Open in yandex maps
Website: https://www.ligand.com
Website: https://www.ligand.com